利用胶原蛋白生物标志物区分银屑病患者和银屑病关节炎患者。
Differentiating patients with psoriasis from psoriatic arthritis using collagen biomarkers.
作者信息
Holm Nielsen Signe, Magee Conor, Groen Solveig S, Sinkevičiūtė Dovilė, Bay-Jensen Anne Christine, Karsdal Morten A, Pennington Stephen R, FitzGerald Oliver
机构信息
Immunoscience, Biomarkers and Research, Nordic Bioscience, Herlev, and Department of Biomedicine and Biotechnology, Technical University of Denmark, Lyngby, Denmark.
UCD Conway Institute, School of Medicine, University College Dublin, Ireland.
出版信息
Clin Exp Rheumatol. 2023 Mar;41(3):574-580. doi: 10.55563/clinexprheumatol/jmt9jv. Epub 2022 Jul 28.
OBJECTIVES
Around 30% of patients diagnosed with cutaneous psoriasis (PsC) will go on to develop psoriatic arthritis (PsA) which includes inflammation of the joints. Collagens are core proteins in all tissues, which are involved in the inflammatory process in both PsC and PsA. The aim of this study is to investigate collagen biomarkers and their potential use in separating the three patient groupings: PsC, PsA and healthy donors.
METHODS
Healthy donors (n=41), patients with PsC (n=30) and patients with PsA (n=30) were recruited. Clinical disease parameters were recorded. Collagen remodelling was measured using ELISA immunoassays which detect the serological anabolic biomarkers quantifying formation of type I, III and IV collagen (PRO-C1, PRO-C3 and PRO-C4 respectively), and the catabolic biomarkers measuring degradation of type I, II, III, IV and X collagen (C1M, C2M, C3M, C4M and C10C respectively).
RESULTS
Patients with PsC and PsA presented lower levels of PRO-C1 and C3M compared to healthy controls (p<0.05-p<0.0001), C1M was higher in PsA compared to healthy controls (p<0.0001) and C2M was all elevated in PsC and PsA compared to healthy controls (p=0.0002 and p=0.0004 respectively), reflecting alterations in the tissues. In addition, C1M was able to separate between PsC and PsA patients with an AUROC=0.664, indicating that this biomarker may be a biomarker of joint involvement.
CONCLUSIONS
This work provides evidence that serum collagen biomarkers are dysregulated in PsC and PsA, as compared to healthy controls. C1M was able to differentiate patients with PsC from PsA and could be a potential biomarker of inflammatory systemic musculoskeletal involvement.
目的
约30%被诊断为皮肤银屑病（PsC）的患者会继而发展为银屑病关节炎（PsA），其中包括关节炎症。胶原蛋白是所有组织中的核心蛋白，参与PsC和PsA的炎症过程。本研究的目的是调查胶原蛋白生物标志物及其在区分三组患者中的潜在用途：PsC患者、PsA患者和健康供体。
方法
招募了健康供体（n = 41）、PsC患者（n = 30）和PsA患者（n = 30）。记录临床疾病参数。使用ELISA免疫测定法测量胶原蛋白重塑，该方法可检测血清合成代谢生物标志物，以量化I型、III型和IV型胶原蛋白的形成（分别为PRO - C1、PRO - C3和PRO - C4），以及分解代谢生物标志物，以测量I型、II型、III型、IV型和X型胶原蛋白的降解（分别为C1M、C2M、C3M、C4M和C10C）。
结果
与健康对照组相比，PsC患者和PsA患者的PRO - C1和C3M水平较低（p<0.05 - p<0.0001），与健康对照组相比，PsA患者的C1M较高（p<0.0001），与健康对照组相比，PsC患者和PsA患者的C2M均升高（分别为p = 0.将患者分为PsC组、PsA组和健康供体组。
方法
招募健康供体（n = 41）、PsC患者（n = 30）和PsA患者（n = 30）。记录临床疾病参数。使用ELISA免疫测定法测量胶原蛋白重塑，该方法可检测血清合成代谢生物标志物，以量化I型、III型和IV型胶原蛋白的形成（分别为PRO - C1、PRO - C3和PRO - C4），以及分解代谢生物标志物，以测量I型、II型、III型、IV型和X型胶原蛋白的降解（分别为C1M、C2M、C3M、C4M和C10C）。
结果
与健康对照组相比，PsC患者和PsA患者的PRO - C1和C3M水平较低（p<0.05 - p<0.0001），与健康对照组相比，PsA患者的C1M较高（p<0.0001），与健康对照组相比，PsC患者和PsA患者的C2M均升高（分别为p = 0.0002和p = 0.0004），反映了组织中的变化。此外，C1M能够区分PsC患者和PsA患者，曲线下面积（AUROC）= 0.664，表明该生物标志物可能是关节受累的生物标志物。
结论
这项工作提供了证据，表明与健康对照组相比，PsC和PsA患者的血清胶原蛋白生物标志物失调。C1M能够区分PsC患者和PsA患者，可能是炎症性全身肌肉骨骼受累的潜在生物标志物。 0002和p = 0.0004），反映了组织中的变化。此外，C1M能够区分PsC患者和PsA患者，曲线下面积（AUROC）= 0.664，表明该生物标志物可能是关节受累的生物标志物。
结论
这项工作提供了证据，表明与健康对照组相比，PsC和PsA患者的血清胶原蛋白生物标志物失调。C1M能够区分PsC患者和PsA患者，可能是炎症性全身肌肉骨骼受累的潜在生物标志物。
Zotero 插件